Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting

Peter Gæde, Pierre Johansen, Christian Klyver Tikkanen, Richard Fulton Pollock, Barnaby Hunt, Samuel Joseph Paul Malkin*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftKommentar/debatForskning

Abstract

In the original publication, Figs. 3 and 5 and the final sentence in the final paragraph of Results/Sensitivity Analyses were incorrectly published. The corrected statement and the figures are given below.

OriginalsprogEngelsk
Sider (fra-til)1319-1321
Antal sider3
TidsskriftDiabetes Therapy
Vol/bind10
Udgave nummer4
DOI
StatusUdgivet - aug. 2019

Fingeraftryk

Udforsk hvilke forskningsemner 'Correction to: Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting' indeholder.

Citationsformater